Cargando…
Cytotoxic Effects of the Dual ErbB Tyrosine Kinase Inhibitor, Lapatinib, on Walker 256 Rat Breast Tumour and IEC-6 Rat Normal Small Intestinal Cell Lines
Lapatinib is an orally administered, dual ErbB1/ErbB2 tyrosine kinase inhibitor (TKI). It is effective in ErbB2 + ve breast cancer treatment. However, lapatinib is associated with diarrhoea with an incidence of 47–75%. The mechanism of ErbB1 TKI-induced diarrhoea remains unclear. ErbB1 or epidermal...
Autores principales: | Wan Mohamad Zain, Wan Nor I′zzah, Bowen, Joanne, Bateman, Emma, Keefe, Dorothy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167933/ https://www.ncbi.nlm.nih.gov/pubmed/31905843 http://dx.doi.org/10.3390/biomedicines8010002 |
Ejemplares similares
-
Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review
por: Raja Sharin, Raja Nur Firzanah Syaza, et al.
Publicado: (2022) -
Aprotinin and growth of Walker 256 carcinosarcoma in the rat.
por: Thomson, A. W., et al.
Publicado: (1977) -
Metabolism of 5-methyltetrahydrofolate by rats bearing the Walker 256 carcinosarcoma.
por: Kennelly, J. C., et al.
Publicado: (1982) -
The Influence of Walker 256 Carcinosarcoma on the Metabolism of Corticosterone and Androstenolone in Rats
por: King, R. J. B., et al.
Publicado: (1963) -
Influence of lodgement site on the proliferation of metastases of Walker 256 carcinoma in the rat.
por: Bellamy, D., et al.
Publicado: (1978)